In immune responses, activated T cells migrate to B-cell follicles and develop into follicular T-helper (T FH ) cells, a recently identified subset of CD4 1 T cells specialized in providing help to B lymphocytes in the induction of germinal centres 1, 2 . Although Bcl6 has been shown to be essential in T FH -cell function, it may not regulate the initial migration of T cells 3 or the induction of the T FH program, as exemplified by C-X-C chemokine receptor type 5 (CXCR5) upregulation 4 . Here we show that expression of achaete-scute homologue 2 (Ascl2)-a basic helix-loop-helix (bHLH) transcription factor 5 -is selectively upregulated in T FH cells. Ectopic expression of Ascl2 upregulates CXCR5 but not Bcl6, and downregulates C-C chemokine receptor 7 (CCR7) expression in T cells in vitro, as well as accelerating T-cell migration to the follicles and T FH -cell development in vivo in mice. Genome-wide analysis indicates that Ascl2 directly regulates T FH -related genes whereas it inhibits expression of T-helper cell 1 (T H 1) and T H 17 signature genes. Acute deletion of Ascl2, as well as blockade of its function with the Id3 protein in CD4 1 T cells, results in impaired T FH -cell development and germinal centre response. Conversely, mutation of Id3, known to cause antibody-mediated autoimmunity, greatly enhances T FH -cell generation. Thus, Ascl2 directly initiates T FH -cell development.
The development of T FH cells is initiated by and dependent on their movement out of the T-cell zone and into the B-cell follicle. This migration process is regulated by upregulation of CXCR5 as well as downregulation of both CCR7 and P-selectin glycoprotein ligand 1 (PSGL1) 2, 6 . T FH cells have unique developmental regulation and Bcl6 was reported to be selectively expressed in T FH cells [7] [8] [9] . However, although Bcl6 potentiates T FH -cell generation in vivo, recent data suggest that it may not regulate CXCR5 upregulation by activated T cells or their migration to B-cell follicles in vivo 3, 4 . Hence, the transcriptional mechanisms underlying initial T FH -cell commitment remain unclear 4 .
Recently, we observed that a bHLH-domain-containing transcription factor, Ascl2, was highly expressed in CXCR5 hi Bcl6 hi cells in comparison with CXCR5 2 Bcl6 2 T cells 4 . Interestingly, CXCR5 1 Bcl6 lo T cells also exhibited upregulation of Ascl2 messenger RNA expression 4 , suggesting that its upregulation may precede that of Bcl6. Moreover, the Ascl2 gene locus was marked with active chromatin marker trimethylated histone H3 lysine 4 (H3K4me3) in T FH and, to a much less extent, T H 2 cells, but not in other T-cell subsets, whereas the other T FHregulating genes Bcl6 (refs 7-9), Maf 10 , Batf 11, 12 and Irf4 (ref. 13) were uniformly associated with H3K4me3 in all T-cell subsets (Extended Data Fig. 1a ). To validate these results, we sorted three subpopulations of cells (CXCR5 2 RFP 2 , CXCR5 1 RFP lo and CXCR5 hi RFP hi ; RFP, red fluorescent protein) from Bcl6-RFP reporter mice immunized with keyhole limpet haemocyanin (KLH) emulsified with complete Freund's adjuvant (CFA) (Fig. 1a ), and found that Ascl2 was highly expressed in T FH cells at both mRNA and protein levels ( Fig. 1b and Extended Data Fig. 1b ). Also, Ascl2 expression was closely correlated with that of CXCR5 ( Fig. 1b) and was higher in T FH cells than in other T-cell subsets (Fig. 1c) . In human T cells, expression of Ascl2 as well as CXCR5 and Bcl6 was found in human tonsil CXCR5 hi PD1 hi T FH cells (Fig. 1d, e ). Collectively, these results suggest that Ascl2 is highly expressed in T FH cells and that its expression may precede that of Bcl6.
Bcl6 and Batf are necessary in T FH -cell development 6, 12 , whereas Stat5 inhibits T FH -cell development 14, 15 . Overexpression of Bcl6 or Batf, or Stat5 deficiency, failed to increase Ascl2 expression (Extended Data Fig. 1c ). None of the known stimuli, including anti-CD3, anti-CD28, anti-ICOS, interleukin (IL)-6 and IL-21, nor their combination, upregulated Ascl2 expression in T cells (Extended Data Fig. 1d ). Ascl2 was previously shown to be a target of canonical Wnt signalling in intestinal stem cells 5 , and we also found that Ascl2 and CXCR5 but not Bcl6 expression in CD4 1 T cells could be upregulated by TWS119 (ref. 16 ; Fig. 1f and Extended Data Fig. 1d , e) or other Wnt agonists (data not shown).
As a first step to examine the function of Ascl2 in T FH cells, retroviral overexpression of Ascl2 was conducted in CD4 1 T cells, leading to substantial induction of CXCR5 expression in over 30% of transduced cells, whereas overexpression of Bcl6, Batf or Maf in purified T cells did not ( Fig. 2a and Extended Data Fig. 2a ). Ascl2 overexpression increased Cxcr5 mRNA expression by ,60 fold ( Fig. 2b) , without affecting Bcl6, Prdm1, Batf, Sh2d1a, Cd40lg, Icos, Pdcd1, Btla and Il21 expression ( Fig. 2c ). CXCR5 expression was equally induced by Ascl2 in wild-type, Bcl6 2/2 and Batf 2/2 CD4 1 T cells in vitro ( Fig. 2d ). Thus, our findings suggest that Ascl2 is unique in its ability to induce CXCR5 protein expression in CD4 1 T cells in vitro. CCR7 and PSGL1 (Selplg) as well as CD25 (Il2ra) and CD122 (Il2rb) expression were downregulated in Ascl2-overexpressing T cells ( Fig. 2e and Extended Data Fig. 2b ), probably accounting for increased follicular homing ability and decreased IL-2 signalling in T FH cells 14, 15, 17 . In addition, T H 1-and T H 17-related signature genes were strongly suppressed by Ascl2 (Extended Data Fig. 2c ).
We then assayed the role of Ascl2 in vivo by transferring Ascl2transduced OT-II cells. In Tcrb 2/2 recipient mice, at day 2 after immunization with 4-hydroxy-3-nitrophenyl (NP)-ovalbumin (OVA) in CFA, neither CXCR5 nor Bcl6 expression were detectable in the vectortransduced control group, whereas Ascl2 overexpression strongly increased in CXCR5 1 Bcl6 lo cells ( Fig. 2f, g) . By contrast, ectopic expression of Bcl6 did not promote T FH -cell generation at this time point (Extended Data Fig. 2d, e ). At day 6 after immunization, Ascl2 overexpression induced a higher percentage of CXCR5 hi Bcl6 hi T FH cells ( Fig. 2f, g) . Accordingly, germinal centre B cells and the total area of the germinal centre at day 8 in C57BL/6 mice receiving Ascl2-transdued T cells were significantly increased ( Fig. 2h-j ). Anti-NP immunoglobulin (Ig)M, IgA, IgG1 as well as IgG3 titres were increased in Tcrb 2/2 mice, whereas IgG2a and IgG2b were not affected by Ascl2-overexpressing T cells ( Fig. 2k ), consistent with IgG2a switching being primarily mediated by extrafollicular T cells 18 .
We next assessed whether Ascl2 could promote T-cell follicular homing in vivo. Ascl2-overexpressing OT-II cells preferentially accumulated in follicles (Fig. 2l ), and even in the germinal centre ( Fig. 2j ), in comparison with control vector-infected T cells. Given that Bcl6 overexpression does not affect early T FH -cell generation (Extended Data Fig. 2d , e) and T FH -cell migration 3 , these observations collectively demonstrate that, by contrast with Bcl6, Ascl2 promotes T-cell migration to the follicles and the initiation of T FH -cell development.
To investigate the mechanism of Ascl2-controlled T FH -cell generation, we performed microarray analysis, and found that the expression of 293 genes was changed by more than twofold by Ascl2 overexpression. Cross-referencing the current data set of Ascl2 versus vector with our previous T FH -cell versus non-T FH -cell data set 4 revealed that 85 of the 293 genes affected by Ascl2 were directly associated with T FH -cell differentiation: 22 genes were upregulated and 63 genes were downregulated 4 (Fig. 3a, b and Supplementary Table 1 ). The chemokine receptors CXCR5 and CXCR4, which are germinal centre T FH -related receptors 19 , were at the top of the upregulated gene list, whereas T H 1related genes (Il12rb1, Tbx21, Ifng and Gzmb) and the T H 17-related aryl hydrocarbon receptor (Ahr) gene were greatly suppressed by Ascl2 ( Fig. 3a) . When comparing Ascl2-RV-GFP-infected (GFP, green fluorescent protein; RV, retroviral vector) CXCR5 1 T cells and CXCR5 2 T cells with in-vivo-generated T FH and non-T FH cells 4 , we found that Ascl2-induced CXCR5 1 T cells were more similar in gene expression to T FH cells (Extended Data Fig. 2f , g), with ,350 genes commonly expressed in these cells (Extended Data Fig. 2h ).
We further examined the effect of Ascl2 on T H 1-, T H 2-and T H 17-cell differentiation. As shown in Extended Data Fig. 3a , overexpression of Ascl2 suppressed both T H 1 and T H 17 differentiation and induced CXCR5 expression. Ascl2 had no effect on TGF-b-induced Foxp3 expression but induced CXCR5 1 regulatory T (T reg ) cells, suggesting that it may also be related to follicular T regulatory (T FR )-cell generation 20 . Under T H 2-polarized conditions, Ascl2 enhanced IL-4 expression, whereas it inhibited the expression of Gata3, IL-5 and IL-13 (Extended Data Fig. 3a -c), in agreement with recent studies that showed IL-4 but not Gata3, IL-5 or IL-13 expression in T FH cells 21 . Also, we observed that Ascl2 increased IL-4 but not IL-21 production in vivo (Extended Data Fig. 3d, e ). Therefore, Ascl2 promotes T FH gene expression and inhibits T H 1-, T H 2-and T H 17-related gene expression. We next assessed Ascl2 target genes by chromatin immunoprecipitation coupled with high-throughput sequencing (ChIP-seq). The analysis revealed a total of 10,028 Ascl2-binding peaks, among which 41% and 36% were enriched in intronic and intergenic regions, respectively ( Fig. 3c ). Only 20% of Ascl2-binding sites were located at promoter regions ( Fig. 3c ). Further comparison of global Ascl2-binding sites with the Ascl2-regulated gene list showed that 145 among 4,374 Ascl2bound genes were transcriptionally regulated by Ascl2 ( Fig. 3d ).
As anticipated, analysis of the Ascl2-binding peaks identified an E-box protein-binding site (59-CANNTG-39) as the consensus motif 5 (Fig. 3e ). Ascl2-binding sites were identified in groups of gene loci including receptor genes (Cxcr5, Cxcr4, Ccr7, Selplg, Il2ra and Il2rb) and inflammatory signature genes (Ifng, Tbx21, Il2 and Rorc) ( Fig. 3f ), but not in some T FH -related genes (Bcl6, Prdm1, Pdcd1, Sh2d1a, Icos, Il21 and Cd40lg) (data not shown).
In particular, the Cxcr5 locus was found to have multiple Ascl2-binding sites in the conserved non-coding sequence (CNS) regions ( Fig. 3f, g) . Moreover, these Ascl2-binding sites at the Cxcr5 locus were confirmed in in-vivo-generated T FH cells: two strong binding sites at intronic regions (CNS5 and CNS4-3), and three at distal promoter region (CNS1-1, CNS1 and CNS2) ( Fig. 3f-h ). Of note, the strongest Ascl2-binding peak was in the CNS5 region, which is consistent with the E47-(bHLH family member) binding site at the Cxcr5 locus 22 (Fig. 3f-h) , implying a potentially redundant role of E2A in transcriptional regulation of the Cxcr5 gene 23 .
To examine the functional significance of Ascl2 binding in regulating CXCR5 expression, we introduced Id3, an inhibitor of the E-box protein 22 , into Ascl2-overexpressing OT-II cells by retroviral infection, and observed a substantial reduction in Ascl2-regulated CXCR5 expression (Extended Data Fig. 4a ); this reduction was due to the inhibition of Ascl2 binding at the Cxcr5 locus, as revealed by ChIP assay (Extended Data Fig. 4b ). Additionally, a luciferase reporter assay showed that CNS5 and CNS1 were responsive to Ascl2 binding (Extended Data Fig. 4c, d ). Together, these results provide evidence that Ascl2 is involved in the direct control of T FH -cell programming. Naive CXCR5 -Bcl6 - All experiments were repeated at least two times with similar results. b, c, g, i, j-l, Graphs show data as mean 6 s.d., two-tailed t-test. NS, not significant.
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As Maf 10 , Batf 11, 12 and IRF4 (ref. 13 ) are required in T FH -cell differentiation, we compared genome-wide occupancy of these transcriptional factors, and found that Ascl2-bound genes hardly correlated with those bound by Maf (Extended Data Fig. 5a ). For instance, IL-21 is directly regulated by Maf 24 , but not by Ascl2 (Extended Data Fig. 5b ). Additionally, there was no binding site for Maf at the Ascl2 locus (data not shown), or vice versa (Extended Data Fig. 5b ), suggesting that Ascl2 and Maf are functionally independent in T FH cells. A large proportion of Ascl2 occupancy colocalized with Batf/IRF4-binding sites (Extended Data Fig. 5c ), including at the CNS of gene loci including Cxcr5, Cxcr4, Ccr7, Selplg, Il2, Il2ra and Il2rb (Extended Data Fig. 5d ), but not at Bcl6, Prdm1 and Maf (Extended Data Fig. 5b ). Interestingly, Batf/IRF4 and Ascl2 peaks were found to be independently localized in T H 1, T H 2 and T H 17 signature genes (Extended Data Fig. 5e-g) , indicating that Batf/IRF4 acts downstream of the T-cell antigen receptor (TCR) in activation of effector programs 25 , whereas Ascl2 mediates suppression. These data strongly support Ascl2 acting as a specific regulator in T FH cells.
T FH cells provide important help to B cells in the induction of efficient anti-virus antibodies during viral infection 6, 26 . To address the functional roles of Ascl2, we generated Ascl2 fl/fl /CD4-Cre mice, in which T cells were developmentally intact (data not shown), and assessed the requirement of Ascl2 in T FH -cell development in vivo with influenza virus infection. After intranasal infection, Ascl2 fl/fl /CD4-Cre mice developed gradual body weight loss from day 3 to day 9, whereas control littermate mice recovered after day 8 (Extended Data Fig. 6a ). At day 9 post-infection (d.p.i.), viral haemagglutinin (HA) mRNA expression in the lungs of Ascl2 fl/fl /CD4-Cre mice was over fivefold higher than that in control mice (Extended Data Fig. 6b ), whereas CXCR5 1 Bcl6 1 T FH cells in lung draining lymph nodes (dLNs) had e, The Ascl2-binding site is identical to the E-box-binding motif. f, Ascl2binding peaks located at gene loci including Cxcr5, Cxcr4, Ccr7, Selplg1, Il2ra, Il2rb, Ifng, Tbx21, Il2 and Rorc. g, Comparison of the mouse Cxcr5 genomic sequence with that of dog, human and rat. Red regions denote CNS region. h, Ascl2-binding sites at the Cxcr5 locus in in-vivo-generated T FH cells as determined by ChIP-qPCR (primers are listed in Supplementary Table 2 ).
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decreased by over 50%, there was a ,3-4-fold decrease in total cell numbers in the absence of Ascl2 (Fig. 4a ), probably accounting for a severe reduction in germinal centre B-cell formation and anti-viral IgG production (Extended Data Fig. 6c, d) . Also, T FH -cell and germinal centre B-cell development in the spleen was reduced in Ascl2 fl/fl /CD4-Cre mice (Extended Data Fig. 6e, f) . No difference was found between CD8 1 T-cell populations in the lung, bronchoalveolar lavage fluid (BALF), spleen and dLNs in Ascl2 fl/fl /CD4-Cre mice and control mice (Extended Data Fig. 6g ), although CD8 1 T-cell activation in the dLNs of Ascl2 fl/fl /CD4-Cre mice was slightly enhanced (Extended Data Fig. 6h ). Moreover, we applied the same assay to tamoxifen-treated mixed bone marrow chimaeric mice receiving both Ascl2 fl/fl /ERT2-Cre and Ascl2 1/1 / ERT2-Cre bone marrow cells, and found a ,50% decrease in T FH cells in the Ascl2 fl/fl /ERT2-Cre counterpart, whereas no defect was found in Ascl2-ablated CD8 1 T cells (Extended Data Fig. 6i, j) .
Because Ascl2 can form heterodimers with three other bHLH family members, including E2-2 (also known as TCF4), E47 (also known as TCF3) and HEB (also known as TCF12) in human cells 5, 23 , this suggests that the partial defect in T FH -cell differentiation in Ascl2 fl/fl /CD4-Cre mice might be caused by compensation from other bHLH members. Indeed, T FH cells and germinal centre responses were normal in Ascl2 fl/fl / CD4-Cre mice after immunization with KLH in CFA (data not shown). A substantial enhancement of E47 expression was noticed in naive T, T FH and even non-T FH cells from Ascl2 fl/fl /CD4-Cre mice compared with control mice (Extended Data Fig. 7a ), and expression of E47 also increased CXCR5 expression in CD4 1 T cells (Extended Data Fig. 7b ), consistent with a recent report that increased E47 activity in Id3 2/2 mice is associated with increased T FH -like cells 22 . Furthermore, we examined T-cell maturation and T FH -cell differentiation in chimaeric mice receiving both Ascl2 fl/fl /CD4-Cre and Ascl2 1/1 /CD4-Cre, or only Ascl2 fl/fl /CD4-Cre bone marrow cells. As shown in Extended Data Fig. 7c, d , in chimaeric mice, Ascl2 deficiency reduced TCR-b hi CD69 lo mature T cells, whereas mice receiving only Ascl2 fl/fl /CD4-Cre cells had fewer defects in T-cell maturation. Accordingly, after immunization with KLH/CFA, T FH -cell generation was inhibited in the Ascl2 fl/fl /CD4-Cre counterpart from mixed chimaeric mice (Extended Data Fig. 7e-g) . These data suggest that Ascl2 deletion at an early developmental stage induces compensatory mechanisms to allow T-cell maturation.
To overcome the inducible compensation mechanism, we deleted the Ascl2 gene acutely using a Cre-expressing retrovirus and examined T FH -cell differentiation. As shown in Fig. 4b , Ascl2 deficiency in this case resulted in an absolute impairment in T FH development in vivo. By contrast, Bcl6-deficient OT-II cells showed intact CXCR5 expression and homing ability at day 3 after immunization (Extended Data Fig. 8a-e ). Moreover, Id3 overexpression impaired T FH -cell generation and germinal centre responses ( Fig. 4c and Extended Data Fig. 9a-c) . Conversely, Id3 deficiency enhanced the T FH -cell population (Fig. 4d) . Together with the observation that Bcl6 overexpression could not rescue Id3-induced T FH blockage (Extended Data Fig. 9d ), Ascl2 seems to have an earlier function than Bcl6 in T FH -cell development. 
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To confirm this, we examined T FH -cell differentiation in either mixed chimaeric mice receiving equal numbers of Ascl2 fl/fl /ETR2-Cre and Ascl2 1/1 /ETR2-Cre bone marrow cells (Fig. 4e ), or intact Ascl2 fl/fl / ETR2-Cre mice (data not shown). After tamoxifen treatment and KLH/ CFA immunization, Ascl2 deletion inhibited T FH -cell differentiation and germinal centre response in vivo ( Fig. 4e and data not shown) . Therefore, these data verify that Ascl2 is intrinsically necessary for T FH -cell differentiation.
We have identified a new player-the Ascl2 transcription factorthat is crucial for T FH -cell development and function. On the one hand, similar to Bcl6, Ascl2 acts as a novel suppressor of T H 1-, T H 2-and T H 17-cell differentiation. On the other hand, Ascl2 uniquely regulates T FH -cell migration and development by increasing CXCR5 and CXCR4 expression, and suppressing CCR7 and PSGL1 expression, and IL-2 signalling. Our data indicate that Ascl2 and Bcl6 act to program T FHcell generation. Activated T cells by antigen-presenting cells gain Ascl2 expression, which allows their migration towards B-cell follicles. At the T-B border, cognate B cells provide another signal for precursor T FH cells to increase Bcl6 expression, which completes T FH polarization and germinal centre formation. Therefore, Id3 and Ascl2 may serve as an early checkpoint during T FH -cell development in promoting appropriate antibody responses to infection while keeping autoimmune diseases in check (Extended Data Fig. 10 ). Further investigation into this axis may offer new ways to modulate antibody responses in infection and autoimmunity.
METHODS SUMMARY
Mice, immunization and infection. Ascl2 fl/fl mice were generated previously 5 and had been backcrossed with C57BL/6 for at least six generations. Mice were immunized with antigens emulsified in CFA subcutaneously (100 ml each mouse). Influenza virus A/Puerto Rico/8 (PR8, H1N1) was purchased from Charles River Laboratories. Mice were anaesthetized by intraperitoneal injection with ketamine and infected intranasally with a dose of PR8 influenza virus 27 lethal to 50% of animals tested (LD 50 ) of 0.5. ChIP-seq. ChIP-seq was performed as described previously 28 . The DNA fragments were sequenced with an Illumina 1G Analyzer at the Institute for System Biology. The output of the Solexa Analysis Pipeline was converted to browser-extensible data (BED) files, and the data were viewed in the UCSC genome browser. Statistics. Unless specifically indicated, comparison between different groups was conducted with Student's t-tests. All P values below 0.05 were considered significant. Statistical analysis was performed with Graphpad Prism 6.
METHODS
Mice. Mice were housed in specific pathogen-free animal facilities at the MD Anderson Cancer Center and Tsinghua University, and were used according to protocols approved by the Institutional Animal Care and Use Committee. Six to eight week old mice were used for all experiments, and were randomly allocated into treatment groups. C57BL/6 mice were from the National Cancer Institute. ETR2-Cre, CD4-Cre, OT-II, B6SJL, Tcrb 2/2 , Rag1 2/2 and Batf 2/2 mice were from Jackson Laboratories. The Ascl2 fl/fl mice were generated previously and had been backcrossed with C57BL/6 for at least six generations 5 . Ascl2 fl/fl mice were bred with CD4-Cre mice to generate Ascl2 fl/fl /CD4-Cre and Ascl2 1/1 /CD4-Cre control mice. Ascl2 fl/fl mice were crossed with ETR2-Cre mice to generate Ascl2 fl/fl /ETR2-Cre and Ascl2 1/1 / ETR2-Cre control mice. Ascl2 deletion in Ascl2 fl/fl /ETR2-Cre cells was achieved by administering 200 ml tamoxifen (5 mg ml 21 ) in sunflower seed oil subcutaneously or intraperitoneally (i.p.) every other day for a total of 5 days. KLH, NP-KLH, OVA and NP-OVA Immunization. Mice and their wild-type controls (6-8 weeks old; three per group) were immunized with antigen (0.5 mg ml 21 ) emulsified in CFA (0.5 mg ml 21 ) subcutaneously (100 ml per mouse). After immunization, these mice were killed and analysed individually. Germinal centre B cells were determined by staining with FITC-labelled anti-GL7, PE-labelled anti-FAS and PerCP-labelled anti-B220 monoclonal antibody (Pharmingen). T FH cells were determined by staining with PerCP-labelled anti-CD4 monoclonal antibody and biotinylated anti-CXCR5 monoclonal antibody (Pharmingen), followed by APClabelled streptavidin (Jackson ImmunoResearch Laboratories) and surface staining by PE-labelled anti-PD1 monoclonal antibody or intracellular staining by PElabelled anti-Bcl6 monoclonal antibody (Pharmingen). Sera from immunized mice were collected, and antigen-specific IgM, IgA, IgG1, IgG3, IgG2a and IgG2b antibodies were measured by using ELISA. Briefly, isotype-specific antibodies to NP were measured in plates coated with NP 4 -BSA using the SBA Clonotying System (Southern Biotech). Titres were presented as the maximum serum dilution exceeding 1.5-fold above the average background. KLH-or OVA-specific titres were measured in a threefold serial dilution onto plates pre-coated with 100 mg ml 21 KLH or OVA. Influenza virus infection. Influenza virus A/Puerto Rico/8 (PR8, H1N1) was purchased from Charles River Laboratories. Six to eight week old Ascl2 fl/fl /CD4-Cre mice (3-5 mice per group) were anaesthetized by i.p. injection with ketamine and infected intranasally with a dose of PR8 influenza virus 27 lethal to 50% of animals tested (LD 50 ) of 0.5. Mice were monitored daily, and weight loss was recorded. To analyse influenza-virus-specific germinal centre responses, T FH and germinal centre B cells from lung mediastinal lymph nodes and spleens were analysed by flow cytometry. BALF and sera were collected from virus-infected mice on 9 d.p.i. Virus-specific IgG antibodies were measured using ELISA. Briefly, serum samples were added in a threefold serial dilution onto plates pre-coated with heat-inactivated virus. Bound antibodies were detected by the incubation of horseradish-peroxidaseconjugated anti-mouse total IgG (1:10,000; Southern Biotech) antibodies. Lung viral titre was monitored by examining influenza virus HA and neuraminidase (NA) gene expression using real-time RT-PCR as previously described 27 . Retroviral transduction and T-cell differentiation. Naive CD4 1 CD25 2 CD44 low CD62L high T cells from Ascl2 fl/fl /OT-II, OT-II or C57BL6 mice were FACS sorted and activated with plate-bound anti-CD3e (clone, 2C11) and anti-CD28 (clone, 37.51) under neutral conditions. Thirty-six hours after activation, cells were infected by retroviruses Ascl2-RV-GFP, Bcl6-RV-GFP, Batf-RV-GFP, Maf-RV-GFP, Id3-RV-GFP, Cre-RV-GFP, E47-RV-CFP (a gift from Y. Zhuang) or control empty vector (empty-RV-GFP or empty-RV-CFP). One day after infection, GFP cells were FACS sorted for adoptive transfer, or followed by re-stimulation with pre-coated anti-CD3e. Also, virus-infected cells were polarized under T H 1 (IL-12, anti-IL-4), T H 2 (IL-4, anti-IFN-c), T H 17 (TGF-b, IL-6, IL-23, anti-IL-4, anti-IFN-c) and T reg (TGF-b) conditions. Four days after culture, cells were re-stimulated with PMA and ionomycin in the presence of Golgi-stop for 4 h, after which IFN-c-, IL-4/IL-5/ IL-13-, IL-17-and Foxp3-expressing cells were analysed using intracellular staining. Cytokines including IL-4, IL-5 and IL-13 from Ascl2-RV-GFP-infected T H 2 cells were measured by ELISA. Cell transfer numbers for different cells were as follows: 1 3 10 5 for GFP 1 T cells; 8 3 10 6 for bone marrow cells. Mixed chimaeric bone marrow mice. To generate mixed bone marrow chimaeras, T-cell-depleted bone marrow cells were obtained from Ascl2 fl/fl /CD4-Cre or Ascl2 fl/fl / ERT2-Cre and their respective congenic wild-type (CD45.1 1 CD45.2 1 ) mice, and mixed at a ratio of 1:1 before being transferred into irradiated Rag1 2/2 (750 rad) mice. Six to eight weeks later, the reconstituted mice were subject to immunization and analysis as described earlier.
Microarray and ChIP-seq. Total cellular RNA was extracted from cells transduced with vector or Ascl2-expressing retrovirus that were purified by their expression of GFP marker with TRIzol reagent (Invitrogen). DNA microarray labelling and analysis were performed by microarray core at the Institute for System Biology. Approximately 10 mg of RNA was labelled and hybridized to GeneChip Mouse Gene 1.0 ST Array (Affymetrix) according to the manufacturer's protocols. Expression values were defined with GeneChip Operating Software (GCOS) software.
ChIP-seq was performed as described previously 28 . Briefly, sorted T cells were fixed by 1% paraformaldehyde, and this was followed by digestion with Mnase cocktail (Active motif). Chromatin from 5 3 10 6 cells was used for each ChIP experiment. Antibodies against H3K4me3 (catalogue no. 07-473, Millipore), H3K27me3 (catalogue no. 07-449, Millipore) and Ascl2 monoclonal antibody (clone 7E2, Millipore) were used. The pull-down DNA fragments were blunt-end ligated with Solexa adaptors, and amplified for sequencing. The DNA fragments were sequenced with an Illumina 1G Analyzer at the Institute for System Biology. The output of the Solexa Analysis Pipeline was converted to browser-extensible data (BED) files, and the data were viewed in the UCSC genome browser. Immunohistochemistry. The protocol for immunohistochemical staining was as described previously 30 . Staining reagents included biotinylated PNA (Vector), AlexaFluor 647 anti-B220, biotinylated anti-IgD, AlexaFluor 488 anti-CD45.2 (Biolegend), and streptavidin AlexaFluor 568 (Invitrogen). All stained slides were mounted with ProlongGold antifade reagents (Invitrogen) and examined with an Olympus FV1000 confocal system. Real-time RT-PCR analysis. Reactive tonsils were obtained from children undergoing elective tonsillectomy after informed consent in a protocol approved by the Institutional Review Board 20 . Total RNA was extracted with Trizol reagent (Invitrogen). Oligonucleotide (dT) and MMLV reverse transcriptase (Invitrogen) were used to generate cDNA. Gene expressions were examined using the iQ SYBR real-time kit (Bio-Rad Laboratories). The data were normalized to a reference gene: b-actin. The primer pairs for real time RT-PCR analysis of Bcl6, Batf, CXCR5, IL-21, IL-4, Gata3, IFN-c, T-bet, Il-17A and RORc were previously described 4 . The primer pair for detection of mouse Ascl2 was: forward, 59-CGCTGCCCAGAC TCATGCCC-39; reverse, 59-GCTTTACGCGGTTGCGCTCG-39. Statistics. Unless specifically indicated otherwise, comparison between two different groups was done with unpaired two-tailed Student's t-tests or two-way analysis of variance (ANOVA). All P values below 0.05 were considered significant. Statistical analysis was performed with Graphpad Prism 6. 
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